Xuechao Xing

Xuechao Xing is an accomplished medicinal chemist currently serving as the Director of Medicinal Chemistry at Medicilon Inc. since April 2024. Previously, Xuechao worked as a Principal Research Scientist at Enanta Pharmaceuticals from September 2014 to April 2024, contributing to significant projects such as the development of EDP-235, a potent 3CLProtease inhibitor for COVID-19, which showed positive results in a Phase II trial. Prior to Enanta Pharmaceuticals, Xuechao was a Principal Investigator at Brigham and Women's Hospital from November 2001 to May 2014, where responsibilities included designing medicinal chemistry plans, analyzing high-throughput screening hits, and optimizing lead compounds for preclinical studies. Xuechao Xing holds a PhD in Organic Chemistry from the University of Essen and Max-Planck Institute for Radiation Chemistry in Germany, along with a Master's degree in Chemistry from East China University of Science and Technology.